Design of the FemCure study:prospective multicentre study on the transmission of genital and extra-genital Chlamydia trachomatis infections in women receiving routine care by Dukers-Muijrers, Nicole H.T.M. et al.
  
 
Design of the FemCure study
Citation for published version (APA):
Dukers-Muijrers, N. H. T. M., Wolffs, P. F. G., Eppings, L., Götz, H. M., Bruisten, S. M., Schim van der
Loeff, M. F., ... Hoebe, C. J. P. A. (2016). Design of the FemCure study: prospective multicentre study on
the transmission of genital and extra-genital Chlamydia trachomatis infections in women receiving routine
care. BMC Infectious Diseases, 16, [381]. https://doi.org/10.1186/s12879-016-1721-x
Document status and date:
Published: 08/08/2016
DOI:
10.1186/s12879-016-1721-x
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
STUDY PROTOCOL Open Access
Design of the FemCure study: prospective
multicentre study on the transmission of
genital and extra-genital Chlamydia
trachomatis infections in women receiving
routine care
Nicole H. T. M. Dukers-Muijrers1,2*, Petra F. G. Wolffs2, Lisanne Eppings1,2, Hannelore M. Götz3,4,5, Sylvia M. Bruisten6,
Maarten F. Schim van der Loeff7,8, Kevin Janssen2, Mayk Lucchesi2, Titia Heijman9, Birgit H. van Benthem4,
Jan E. van Bergen4,10,11, Servaas A. Morre12,13, Jos Herbergs14, Gerjo Kok15, Mieke Steenbakkers1,
Arjan A. Hogewoning9, Henry J. de Vries7,8,9,16 and Christian J. P. A. Hoebe1,2
Abstract
Background: In women, anorectal infections with Chlamydia trachomatis (CT) are about as common as genital CT, yet
the anorectal site remains largely untested in routine care. Anorectal CT frequently co-occurs with genital CT and may
thus often be treated co-incidentally. Nevertheless, post-treatment detection of CT at both anatomic sites has been
demonstrated. It is unknown whether anorectal CT may play a role in post-treatment transmission. This study,
called FemCure, in women who receive routine treatment (either azithromycin or doxycycline) aims to understand
the post-treatment transmission of anorectal CT infections, i.e., from their male sexual partner(s) and from and to the
genital region of the same woman. The secondary objective is to evaluate other reasons for CT detection by nucleic
acid amplification techniques (NAAT) such as treatment failure, in order to inform guidelines to optimize CT control.
Methods: A multicentre prospective cohort study (FemCure) is set up in which genital and/or anorectal CT positive
women (n = 400) will be recruited at three large Dutch STI clinics located in South Limburg, Amsterdam and Rotterdam.
The women self-collect anorectal and vaginal swabs before treatment, and at the end of weeks 1, 2, 4, 6, 8, 10, and 12.
Samples are tested for presence of CT-DNA (by NAAT), load (by quantitative polymerase chain reaction -PCR),
viability (by culture and viability PCR) and CT type (by multilocus sequence typing). Sexual exposure is assessed
by online self-administered questionnaires and by testing samples for Y chromosomal DNA. Using logistic regression
models, the impact of two key factors (i.e., sexual exposure and alternate anatomic site of infection) on detection of
anorectal and genital CT will be assessed.
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Discussion: The FemCure study will provide insight in the role of anorectal chlamydia infection in maintaining the CT
burden in the context of treatment, and it will provide practical recommendations to reduce avoidable transmission.
Implications will improve care strategies that take account of anorectal CT.
Trial registration: ClinicalTrials.gov Identifier: NCT02694497.
Keywords: Chlamydia trachomatis, Anorectal, Genital, Transmission, Heterosexual
Background
Chlamydia trachomatis (CT) infection is the most com-
monly reported sexually transmitted infection (STI) in
high income countries; about 3-4 % of 18–24 year olds
in the general population of European Union Member
States are infected with CT [1–3]. Most infections occur
in the young and the burden of sequelae is largest in
women [4–6]. CT is a major cause of pelvic inflamma-
tory disease, ectopic pregnancy and tubal infertility in
women and of urethritis in men and proctitis in men
who have sex with men (MSM) [4]. CT repeat infections
are common in women [7], and are related to an in-
creased risk of adverse reproductive outcomes [8].
Moreover, CT genital and anorectal infections facilitate
the acquisition and transmission of HIV infection [4, 9].
Much of the burden of bacterial STI results from their
frequent initial asymptomatic nature, and many infec-
tions remain undiagnosed [4]. Chlamydia is widely rec-
ognized as a public health problem and many countries
have adopted control strategies to limit its spread. Mea-
sures include active testing in young people, additional
population screening programs and enhanced screening
activities at general practitioners [10–12]. Yet, it is clear
that we fail to sufficiently limit the ongoing transmission
as CT prevalence and incidence rates remain high.
Two knowledge gaps can be identified in the evidence
for CT control strategies. First, we do not understand
the role of anorectal CT in women in overall CT spread.
In women, anorectal infections are about as common as
genital infections, with proportions positive ranging be-
tween 7 - 27 % of anorectally tested women [13-25]. Yet,
most anorectal CT infections remain undetected as gen-
eral practitioners, hospital and population testing initia-
tives ignore anorectal CT and largely focus on genital
CT [26]. STI clinics do test women at the anorectal site
on indication, i.e., when they report anal sex or symp-
toms. Still, with half of all anorectal CT occurring in
women who do not report anal sex, many anorectal in-
fections are left untested. Second, we do not know
whether transmission of CT can occur in the weeks fol-
lowing currently recommended treatment. Prior studies
have shown considerable detection of both anorectal
and genital CT after treatment in women and men
[27–32]. Detection rates depended on the number of
samples taken and type of tests used, demonstrating up
to 40 % of treated cases having at least one positive sam-
ple when sampled multiple times within 8 weeks [27].
Indeed, repeat genital CT infections are common follow-
ing treatment, varying between 10 % and 30 % when re-
testing CT positive treated women between 3 months
and a year later [33]. Guidelines advise such re-
screening at 3 months after a CT diagnosis. Yet, in prac-
tice, re-screening occurs in less than a third of patients
in the Netherlands [34]. Current care does not include a
routine re-test of patients within 3 months of treatment
[35-37] nor does it include an anorectal re-test 3 months
after the genital CT treatment. Many uncertainties exist
on the clinical relevance of a post-treatment CT detec-
tion. It is unknown whether it reflects transmission after
sexual exposure or self-infection. It is also unknown
whether detection of CT nucleic acids indicates viable or
nonviable CT and what organism loads are present [38].
Suboptimal treatment may possibly play a role, but evi-
dence is inconclusive leading to considerable debate on
this issue [39–42].
The current lack of anorectal testing of patients at-
tending STI care may not pose much of a problem when
the anorectal infections are effectively treated together
with the genital CT infections, as 75-95 % of anorectal
CT co-occur with genital CT [13]. Yet, it is unknown
whether treatment efficacy is sufficient. Moreover, the
lack of understanding what observed CT positivity after
treatment means in terms of transmission and morbid-
ity, may preclude any conclusions on the potential posi-
tive effect of co-incidental anorectal CT treatment. Our
understanding of how anorectal CT detection may ex-
plain CT transmission is incomplete [27]. (Un-and
under) treated anorectal infections may contribute to
ongoing transmission of genital and anorectal CT in the
population at risk, both between partners and between
anatomic sites within an individual. The FemCure study
is set up to contribute to filling these knowledge gaps
and contribute to the evidence for effective CT control
strategies.
Methods/design
Study aim
The aim of the FemCure study is to understand the
transmission of anorectal CT infections in women who
receive routine care, specifically from their male sexual
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partners and to and from the anal and genital region
within the same woman, and also includes an evaluation
of treatment-type impact.
During a period of 4 years (2016–2019) the following
study questions will be addressed:
1) What is the detection rate of anorectal and genital
CT in heterosexual women in the 12 weeks after
receiving standard of care for a genital/anorectal CT
infection?
a. What is the risk of incident CT detection after
sexual exposure (i.e., transmission from a male
partner)?
b. What is the risk of incident CT detection in
alternate anatomic sites in women (i.e., transmission
from one to another anatomic site in the same
woman/self-infection)?
2) What are the co-factors?
3) Is treatment-type associated with risk of repeat
genital/anorectal CT detection?
4) Which practical recommendations can be
formulated for professionals involved in CT control
(STI clinic workers, general practitioners,
gynaecologists, medical microbiologists).
Design
To reach the study aim, a multicentre prospective cohort
study is set up among women visiting Dutch STI clinics.
Setting
Women will be recruited from STI clinics of the Public
Health Services (GGD) in Rotterdam, Amsterdam and
South Limburg. According to our national registry these
three participating clinics tested 31200 women for CT in
2014. Of these, 3718 (12 %) women tested CT positive
[5]. Part of these women was also tested anorectally
demonstrating about 600 anorectal CT infections.
Among all CT positives, the majority was young (i.e.,
71 % were under 25 years of age, 20 % were between 25
and 29 years of age). A substantial part of the women
who tested CT positive had a low socio-economic status
(SES), based on the SES score of their neighbourhood of
residence (www.scp.nl), i.e., 21 % had low SES and 13 %
had very low SES. Of the positive women, the majority
was Dutch (61 %). Of the remainder of the positive
women, 10 % were Surinamese, 4 % were Antillean, 3 %
were Moroccan, and 1 % were Turkish. The majority of
the non-Dutch ethnic groups were second generation
migrants.
Study population
The eligible study population is likely to reflect the
current STI clinic populations. Eligible are heterosexual
women with symptomatic or asymptomatic genital and/
or anorectal CT infection, who are not pregnant and
18 years or older. Exclusion criteria are recent reported
use of antibiotics, HIV positivity, syphilis and infection
with Neisseria gonorrhoea. As single anorectal CT is un-
common and around 75-95 % of genital CT positive
women also have anorectal CT [13–25], it is expected
that of the included women only few will have anorectal
CT only. The majority (75 %) expectedly will have ano-
rectal CT in combination with genital CT, and most of
the remainder will have genital CT only at inclusion in
the study. Treatment occurs according to regular care
and international guidelines [35–37]. Women who are
anorectally tested in routine care and found anorectal
CT positive are treated with a 7-day course of doxycyc-
line 100 mg twice daily with the first dosis being directly
observed. All other women receive a directly observed
single dose of azithromycin 1000 mg [35–37]; these
women tested genitally CT positive in routine care and
were either anorectally untested in routine care or were
tested anorectally CT negative.
Recruitment
Participants will be recruited upon return for treatment
at three STI clinics. Recruitment of women is expected
to take approximately 1 year. At recruitment, the women
receive information on the study and are referred to the
study website: www.femcure.nl.
Inclusion and follow-up
Participation starts after written informed consent. The
women will be followed for 3 months when they collect
samples and complete self-administered questionnaires
(see Table 1). In order to motivate participants to
complete follow-up, short text messaging (SMS) re-
minders are used, simple home-collection of samples is
used [43, 44], and online questionnaires are used.
Follow-up will entail 3 clinic visits, at weeks 4, 8, and 12.
This last visit is also a routine STI clinic visit for repeat
testing. Small incentives are provided (€10) at each
follow-up clinic visit. Inclusion and follow-up visits are
conducted by highly experienced nurses trained in STI
care including motivational interviewing. Further, to in-
crease the number of participants with complete follow-
up data, the women who are included but who do not
show up at week 4 for the clinic visit will be replaced by
a new participant.
Sample collection
Women will collect self-administered anorectal and va-
ginal swabs at 8 time-points at home and at the STI
clinic (see Table 1) [43, 44]. A test-package with clear in-
structions is provided for self-collection at home. At
clinic visits, the participants take an additional self-
administered anorectal and vaginal swab that is stored in
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a different buffer and cooled immediately at −80 °C, to
allow CT viability testing. Samples are sent in batches by
courier to the laboratory for processing. Each clinic visit,
also a pharyngeal nurse-taken swab is collected for later
testing.
Laboratory testing
All samples are tested using routinely used nucleic acid
amplification tests (NAAT) for the presence of CT
(Table 1). The frozen samples from participants testing
CT positive by routine NAAT are further tested for viabil-
ity with viability polymerase chain reaction (vPCR; unpub-
lished protocol, P. Wolffs, K. Janssen, N. Dukers-Muijrers,
C. Hoebe, Medical Microbiology, MUMC, Maastricht) di-
rected at the detection of DNA inside intact microbial
cells or with culture [45]. A positive culture or vPCR re-
sult implies the presence of viable and infectious CT and
provides information on the potential clinical relevance of
the infection. Other non-routine measures include the
CT-DNA load that will be assessed using quantitative
NAAT. The CT genotype will be determined using high
resolution multilocus sequence typing (hr-MLST) [46].
Strain typing is here specifically used to confirm self-
infection or persistence. A selection of samples is tested
for Y chromosome DNA as a marker for semen exposure
to assess underreporting of sexual behaviour [47].
Collection of self-reported data
Data will be collected by online self-administered ques-
tionnaires at inclusion, and during follow-up around the
sampling times. The questionnaire at inclusion contains
questions on age, ethnicity, gender, socio-economic sta-
tus. All questionnaires contain questions on number of
partners, and for each sexual partner the sexual behav-
iour (genital, anal, oral sex) in the past two weeks, test-
ing for STI and treatment. It also includes questions on
behaviours such as contraceptive use, antibiotic use,
drug use, STI testing during follow-up, and on list of
symptoms. Further, participant data will be collected
concerning treatment type and compliance. For the pur-
pose of process evaluation, a few questions are included
that address acceptability and possible difficulties en-
countered related to the participation in the study. Each
participant has a study code under which all data (sam-
ples and questionnaires) are collected and analysed.
Outcome in analyses
Detection of anorectal and genital CT by NAAT (pri-
mary outcome), viability and load (secondary outcomes).
Definition of transmission
Transmission is defined as an observed incident CT de-
tection post-treatment (a) after having sex with a source
partner (by self-reported behaviour and biomarker-
validation), and (b) when another anatomical source lo-
cation tested positive, i.e., self-infection. In such cases,
self-infection is considered likely when CT strain types
do not differ between anatomic sites of a woman. Sam-
ples with CT detection that follow a sample with CT de-
tection may represent persistence and are considered
not indicative for transmission. In such cases, persist-
ence is considered likely when CT strain types do not
differ in a woman over time.
Defining sexual exposure
In women, the process of CT acquisition from an in-
fected partner, i.e., via sex, is defined based on sexual be-
haviour data from the detailed and frequent
questionnaires and by biomarker assessment. The actual
CT status of the partner during follow-up will in most
cases be unknown. Hence, the sexual behaviour that is
reported during follow-up may also include sex with CT
negative partners. The risk estimate for the association
between sexual exposure and incident CT detection
Table 1 Overview of FemCure study time points at inclusion (pre-treatment) and during follow-up until 12 weeks post-treatment
Pre-treatment Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12
T0 (inclusion) T1 T2 T3 T4 T5 T6 T7
Location Clinic Home Home Clinic Home Clinic Home Clinic
Number of anorectal samples collected per womana 2 1 1 2 1 2 1 2
Number of genital samples collected per womana 2 1 1 2 1 2 1 2
Number of pharyngeal swabs collected per womanb 2 1 1 1
NAAT on self-collected swabs X X X X X X X X
Viability testing on self-collected swabs X X X X
Chlamydia organism load, MLSTc and semen biomarkerc
testing on self collected swabs
X X X X X X X X
(Online) short questionnaire X Xd X X X X X X
aSelf-collected swabs
bNurse taken swabs; stored for later testing
cIn subset only
dAssessing treatment compliance and sexual behavior (in short) at week 1. At the other weeks, detailed self-reported sexual behaviors and symptoms are assessed
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reflects the risk of transmission given this sexual practice
and regardless of the partner's CT status. This will be a
good proxy to the actual transmission probability for a
given sexual practice in ‘real life’ and is most relevant in
the practical care setting where information on sexual
behaviour is routinely asked about and registered and
partners’ CT status is often lacking. To validate sexual
exposure from a man, especially to indicate underreport-
ing, biomarker validation is applied.
Defining alternate anatomic site exposure
The process of CT anorectal acquisition from her own
genital CT infection and vice versa is defined based on
the CT test results. Exposure is defined as presence of
CT detection at the other anatomic site at the same
sampling moment and/or the previous sampling mo-
ment. CT typing results are also used to confirm the link
between the two detections.
Treatment failure
A possible reason for CT detection after treatment,
other than transmission, may be treatment failure.
Whether antimicrobial treatment failure for CT plays a
role remains poorly understood [41]. There is no evi-
dence of homotypic anti-microbial resistance and testing
for antimicrobial resistance for CT is not routinely avail-
able. It will therefore be quite difficult to microbiologic-
ally ascertain treatment failure as a reason for CT
detection. Still, there is current debate on what is the ap-
propriate treatment for anorectal CT infection [39–41].
Some studies conclude that azithromycin is a suboptimal
treatment [28, 30–32], while another study found doxy-
cycline and azithromycin treatments to be equally effect-
ive for anorectal CT [29]. In some countries (the
Netherlands, Australia, UK), guidelines for anorectal CT
treatment have recently shifted from azithromycin
1000 mg single dose to doxycycline 100 mg twice daily
for 7 days [36, 37], while in the US these treatments are
considered to be equally effective first line treatments
[35]. These recommendations reflect concern that azi-
thromycin efficacy for anorectal infections may be less
than expected. Yet, there are no robust studies showing
conclusive evidence concerning a suboptimal effect of
any type of treatment or to prefer one over the other
treatment. The current study attempts to inform this de-
bate by analysing the association between treatment and
CT detection in a sub analysis.
Statistical analyses
The main study questions will be answered by analysing
the data on the level of episodes. For each incident CT
detection, the information of the preceding sample re-
sults, and the sexual behaviour information from the
preceding 2-week interval, is analysed. Using mixed
models, univariate and multivariate logistic regression
analyses will be applied to calculate rates of incident CT
anorectal and genital detection, controlling for repeated
measurements in a person. Thereby, the relative contri-
butions are assessed of sexual exposure and of alternate
anatomic site exposure, i.e., sexual transmission and
self-infection. This will be done by including different
exposures as co-factors and this will also be done
comparing categories of sexual exposure, anatomic
site exposure, and both exposures compared to no
such exposure (see Table 2).
Risks will be expressed by odds ratio‘s and 95 % confi-
dence intervals. Co-factors (such as age, but also
treatment-type) will be included in the models to ac-
count for their potential role as a confounding factor or
effect-modifier in the associations between exposure and
CT detection. Also, these co-factors are assessed for
their association with CT detection.
Sensitivity analyses will be undertaken by varying the
definition of the outcome (primary and secondary out-
comes) and by varying the definition of the sexual ex-
posure (e.g., including and excluding sexual practices).
By performing a (limited) process evaluation of our
study, we will obtain insights in the factors that have af-
fected participation and possible loss-to-follow-up.
In a sub analysis, in which the unit of analysis will be
an individual woman (not the 2-week episodes), a head-
to-head comparison of the two treatments will be
conducted.
Numbers and power
Based on the power calculations we need to include 300
- 380 women with full retention, to be able to answer
the main study question and the sub-analyses with suffi-
cient power (at least 70 %) to show statistically signifi-
cant (5 %) associations of a relevant size. This was
calculated in different scenarios by varying the assump-
tions in number of women with full data (300–380), the
percentage of CT detections (15-30 %), the percentage
of reported sex during a 2-week episode (20-60 %) and
the percentage of alternate anatomic site exposure
(10-30 %). Accounting for women who are anorectally
CT negative at inclusion, loss-to-follow up, missing
data, and persistence, we need to recruit 400 women
in the study to be able to have sufficient numbers of
samples that can be analysed.
Discussion
The FemCure study will deliver information on the role
of anorectal CT in the transmission of CT. It may guide
further care-optimization for anorectal CT testing and
treatment as in current care women are not routinely
tested anorectally. It will also describe the microbio-
logical specifics of genital and anorectal CT detection
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after treatment, such as on the viability of detected CT,
which is relevant for clinical practice and for healthcare
policy making in order to reduce avoidable transmission.
Strengths
First, this study will generate new information on the
meaning and the cause of CT detection after treatment.
This information goes beyond current state of the art
due to its combination of different laboratory tests
(NAAT, viability, load, typing) to detect CT, and by sam-
pling both anorectal and genital anatomic sites in the
same woman and multiple points in time. Second, the
recruitment at multiple STI clinics, serving ample num-
bers of clients, allows us to study sufficient numbers of
patients in a relatively short time period. Naturally, our
study domain is restricted to patients consulting a STI
clinic, which we consider the relevant population for this
research question. We do not expect that results would
be different for clients consulting a general practitioner
or gynaecologist for their CT infection. Third, the study
nurses and the participants are blinded to the results of
the laboratory testing as testing will be done in batches
afterwards. All data will be handled coded, ensuring the
anonymity of included patients. Fourth, several measures
are taken to optimize reliability and validity of measures
of sexual exposure, including the use of pre-tested ques-
tions using standard terminologies that people have shown
to comprehend, computer-assisted self-interviewing,
using short recall periods (2 weeks), and using an
administration mode that ensures privacy. Also self-
reports are validated by applying biochemical measures.
Although the Y chromosome DNA may not be detected
in all exposures, if it is detected it is used to capture
underreporting and instances of incorrect condom use
or condom failure. These biomarker analyses will be
done on already collected swabs, thus no extra swab is
needed from a participant. Fifth, the research team is
interdisciplinary and highly experienced in CT research
and covers the different areas of expertise needed to
successfully conduct the proposed research. It consists
of members several Dutch Public Health Services, STI
clinics, Medical Microbiological Laboratories, Universities
(including behavioural science), and national institutes
for policy and STI guideline development ensuring
the quality of the study and the valorisation, i.e., the
practical implication of results.
Limitations
First, it cannot be ruled out that some degree of mis-
classification in both exposures and outcomes may
Table 2 Main regression models in FemCure study
Exposure categories Definition in the datab Interpretationc of positive CT test result
Outcome incident genital CT detection
Model 1 Sexual exposurea Genital sexual exposure (at Tx)
Alternate site exposure Anorectal CT positive (at Tx and/or Tx-2)
Model 2 No exposure No genital sexual exposure (at Tx) AND anorectal
CT negative (at Tx and Tx-2)
Persistence
Genital sexual exposure only Genital sexual exposure (at Tx) AND anorectal CT
negative (at Tx and Tx-2)
Sexual transmission
Anorectal site exposure only No genital sexual exposure (at Tx) AND anorectal
CT positive (at Tx and/or Tx-2)
Transmission from anorectal site
Sexual exposure and anorectal
site exposure
Genital sexual exposure (at Tx) AND anorectal CT
positive (at Tx and/or Tx-2)
Sexual transmission AND/OR Transmission
from anorectal site
Outcome incident anorectal CT detection
Model 1 Sexual exposurea Anorectal sexual exposure (at Tx)
Alternate site exposure Genital CT positive (at Tx and/or Tx-2)
Model 2 No exposure No anorectal sexual exposure (at Tx) AND genital
CT negative (at Tx and Tx-2)
Persistence
Anorectal sexual exposure only Anorectal sexual exposure (at Tx) AND genital CT
negative (at Tx and Tx-2)
Sexual transmission
Genital site exposure only No anorectal sexual exposure (at Tx) AND genital
CT positive (at Tx and/or Tx-2)
Transmission from genital site
Sexual exposure and genital
site exposure
Anorectal sexual exposure (at Tx) AND genital CT
positive (at Tx and/or Tx-2)
Sexual transmission AND/OR Transmission
from genital site
aBased on self-administered questionnaires and semen biomarker assessment
bTx: test result at the sampling; Tx-2: test result at the sampling two weeks earlier
cStrain typing is used to further aid interpretation of the observed positive CT test result, specifically to confirm self-infection (i.e., strain types do not differ
between anatomic sites) or persistence (i.e., strain types do not differ over time)
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occur. Sexual exposure may be underreported, even
when validity and reliability of the questionnaire data are
optimized and biomarker validation is applied (exposure
misclassification). Also, a woman may clear the CT in-
fection before the sampling occurs (outcome misclassifi-
cation). However, an even more frequent sampling as
already scheduled (at weeks 0,1,2,4,6,8, 10, and 12) was
considered to potentially compromise study inclusion
and retention and would also require more funds than
are currently available.
Second, a randomised controlled trial (RCT) would be
the most suited study design to compare efficacy of
treatments, such as recently reported for genital CT
[48]. The observational FemCure study is not designed
as an RCT as a treatment comparison is not its main
aim and an RCT would require more human and finan-
cial resources than are currently available. Nevertheless,
the role of treatment can and will be evaluated in a sub-
analysis by a head-to-head comparison of treatment-
types. Most of the current studies reporting comparison
of anorectal CT treatments similarly are observational
studies with inherent biases to account for [28–32,
39–41]. By including different anatomic sites and a di-
verse range of laboratory and exposure measures in
the current study, results will add to the existing lit-
erature and will thereby be able to inform the current
debate on treatment failure.
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